DE602004015725D1 - Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors - Google Patents
Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitorsInfo
- Publication number
- DE602004015725D1 DE602004015725D1 DE602004015725T DE602004015725T DE602004015725D1 DE 602004015725 D1 DE602004015725 D1 DE 602004015725D1 DE 602004015725 T DE602004015725 T DE 602004015725T DE 602004015725 T DE602004015725 T DE 602004015725T DE 602004015725 D1 DE602004015725 D1 DE 602004015725D1
- Authority
- DE
- Germany
- Prior art keywords
- tissue factor
- factor inhibitor
- tfpi
- variations
- lyophilized preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title abstract 5
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title abstract 5
- 102000002262 Thromboplastin Human genes 0.000 title 2
- 108010000499 Thromboplastin Proteins 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000007496 glass forming Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43852403P | 2003-01-08 | 2003-01-08 | |
US49454703P | 2003-08-13 | 2003-08-13 | |
US50927603P | 2003-10-08 | 2003-10-08 | |
US51209203P | 2003-10-20 | 2003-10-20 | |
PCT/US2004/000235 WO2004062646A1 (en) | 2003-01-08 | 2004-01-08 | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004015725D1 true DE602004015725D1 (de) | 2008-09-25 |
Family
ID=32719507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004015725T Expired - Lifetime DE602004015725D1 (de) | 2003-01-08 | 2004-01-08 | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors |
Country Status (9)
Country | Link |
---|---|
US (2) | US20040180827A1 (de) |
EP (1) | EP1589949B1 (de) |
JP (1) | JP2008500942A (de) |
AT (1) | ATE404176T1 (de) |
CA (1) | CA2512680A1 (de) |
DE (1) | DE602004015725D1 (de) |
ES (1) | ES2311789T3 (de) |
PT (1) | PT1589949E (de) |
WO (1) | WO2004062646A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
EP2298278B1 (de) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Verhinderung und Reduzierung von Blutverlust und Entzündungsreaktion |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
SI2386310T1 (sl) | 2002-08-28 | 2019-03-29 | Dyax Corp. | Metode za ohranjanje organov in tkiv |
US20050032153A1 (en) * | 2003-04-30 | 2005-02-10 | Ropp Philip A. | Control of cyanate in aqueous urea solutions by non-1,2-ethylene diamine like compounds for the protection of protein/peptide carbamylation |
AU2005277357B2 (en) * | 2004-08-17 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
WO2006081320A2 (en) * | 2005-01-27 | 2006-08-03 | Human Genome Sciences, Inc. | Pharmaceutical formulation |
GB0517688D0 (en) * | 2005-08-31 | 2005-10-05 | Cambridge Biostability Ltd | Improvements in the stabilisation of biological materials |
GB2430880A (en) * | 2005-10-04 | 2007-04-11 | Cambridge Biostability Ltd | Pharmaceutical compositions stabilized in glassy particles |
GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
WO2007103425A2 (en) * | 2006-03-06 | 2007-09-13 | Novartis Ag | Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) |
EP2001500A4 (de) * | 2006-03-10 | 2010-07-28 | Dyax Corp | Formulierungen für ecallantid |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
CN102942597A (zh) * | 2012-10-24 | 2013-02-27 | 江苏大学 | 含氯或氟的五配位咔咯钴配合物及其合成方法 |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
CA2961739C (en) * | 2014-08-20 | 2024-04-30 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
CN108883160B (zh) | 2016-02-24 | 2022-06-28 | 博尔托拉制药公司 | 因子xa解毒剂的冻干制剂 |
EP3710063A1 (de) * | 2017-11-16 | 2020-09-23 | Amgen Inc. | Stabile zusammensetzungen von pegylierten carfilzomib-verbindungen |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US4966852A (en) * | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
DK408089D0 (da) * | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Proteiner |
US5583107A (en) * | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
US5276015A (en) * | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
JP3435946B2 (ja) * | 1994-12-21 | 2003-08-11 | 王子製紙株式会社 | 耐熱性キシラナーゼ |
DK0813525T3 (da) * | 1995-03-10 | 2004-02-16 | Berlex Lab | Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter |
ATE358684T1 (de) * | 1995-06-07 | 2007-04-15 | Novartis Vaccines & Diagnostic | Waessrige formulierung enthaltend tfpi und lösungsvermittlers |
US5721214A (en) * | 1995-06-07 | 1998-02-24 | Cor Therapeutics, Inc. | Inhibitors of factor Xa |
US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
ATE239501T1 (de) * | 1995-06-07 | 2003-05-15 | Chiron Corp | Regulierung der neutrophil elastase synthese und freisetzung |
US5919765A (en) * | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5580107A (en) * | 1995-09-25 | 1996-12-03 | Dell U.S.A., L.P. | Hidden latch hook for portable personal computer and the like |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
US5824660A (en) * | 1996-06-10 | 1998-10-20 | G. D. Searle & Co. | Method of inhibiting glomerulonephritis |
CA2279345A1 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
PL356641A1 (en) * | 1999-12-30 | 2004-06-28 | Chiron Corporation | Methods for pulmonary delivery of interleukin-2 |
DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
WO2003055442A2 (en) * | 2001-10-15 | 2003-07-10 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
-
2004
- 2004-01-08 AT AT04700827T patent/ATE404176T1/de not_active IP Right Cessation
- 2004-01-08 EP EP04700827A patent/EP1589949B1/de not_active Expired - Lifetime
- 2004-01-08 CA CA002512680A patent/CA2512680A1/en not_active Abandoned
- 2004-01-08 JP JP2006500806A patent/JP2008500942A/ja active Pending
- 2004-01-08 ES ES04700827T patent/ES2311789T3/es not_active Expired - Lifetime
- 2004-01-08 DE DE602004015725T patent/DE602004015725D1/de not_active Expired - Lifetime
- 2004-01-08 PT PT04700827T patent/PT1589949E/pt unknown
- 2004-01-08 WO PCT/US2004/000235 patent/WO2004062646A1/en active Application Filing
- 2004-01-08 US US10/753,079 patent/US20040180827A1/en not_active Abandoned
-
2006
- 2006-03-22 US US11/385,873 patent/US20060159679A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060159679A1 (en) | 2006-07-20 |
CA2512680A1 (en) | 2004-07-29 |
EP1589949A1 (de) | 2005-11-02 |
WO2004062646A9 (en) | 2010-11-11 |
ES2311789T3 (es) | 2009-02-16 |
US20040180827A1 (en) | 2004-09-16 |
WO2004062646A1 (en) | 2004-07-29 |
EP1589949B1 (de) | 2008-08-13 |
PT1589949E (pt) | 2008-11-06 |
JP2008500942A (ja) | 2008-01-17 |
ATE404176T1 (de) | 2008-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
PE20040972A1 (es) | Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico | |
WO2007019232A3 (en) | Immunoconjugate formulations | |
UY25055A1 (es) | Formulaciones farmacéuticas que contienen voriconazol | |
AR039688A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
ES2421447T3 (es) | Métodos para proteger frente a apoptosis usando lipopéptidos | |
RS53945B1 (en) | SUPER FAST INSULIN COMPOSITIONS | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
IL208697A0 (en) | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol | |
UY28897A1 (es) | Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb | |
AR038927A1 (es) | Sales de acido organico | |
ATE248187T1 (de) | Echinocandin-kohlenhydrate-komplexe | |
ATE367165T1 (de) | Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen | |
HUP0101899A2 (hu) | Cisztein-aktivitástól függő enzimeket gátló hatású tiadiazolvegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DE60224449D1 (de) | Gebrauchsfertige paracetamol injektionslösungen enthaltend propylenglykol als einziges cosolvens | |
BR0302496A (pt) | Composições farmacêuticas com atividade antibiótica | |
NO20004306L (no) | Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat | |
RU2012122793A (ru) | Композиция, способ и набор для альфа-1 ингибитора протеазы | |
DE60236025D1 (de) | Pharmazeutische zusammensetzung enthaltend l-arginin | |
EP1803445A3 (de) | Stabilisierte lyophilisierte Zubereitungen mit Gewebefaktor-Inhibitor (TFPI) oder Varianten des Gewebefaktor-Inhibitors | |
MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
BR0312452A (pt) | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama) | |
HUP0102792A2 (hu) | Benzotiadiazolszármazékot és karpromamidot tartalmazó szinergetikus hatású mikrobicid készítmény és alkalmazása |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |